How FAI turns a bone-shape problem into a cartilage defect

Pain from femoroacetabular impingement (FAI) is not simply a matter of a 'rough' joint — it is the predictable consequence of an engineering mismatch between the femoral head and the acetabular socket.

In a normally shaped hip, the femoral head is a near-perfect sphere that rotates smoothly inside its socket. In cam-type FAI, the head is non-spherical — flattened or enlarged at its junction with the neck — so that on deep flexion and internal rotation it jams against the anterosuperior rim of the acetabulum like an eccentric shaft in a bearing. Each repetition drives shear stress into the cartilage at that contact point, eventually separating a full-thickness disc of articular surface from the underlying bone at precisely that location.

Pincer morphology produces a slightly different pattern: the acetabular rim over-covers the femoral head, so the labral-chondral junction at the rim edge is crushed on movement rather than sheared. The result is a narrower defect, but it is equally focal and isolated.

Both mechanisms produce a lesion that is spatially constrained — a discrete hole or flap in otherwise healthy cartilage — rather than the diffuse, map-like thinning seen across the whole joint surface in osteoarthritis. That anatomical specificity is what makes focal cartilage treatment a realistic option.

One caveat follows directly from the mechanics: any repair tissue placed inside the defect will face the same abnormal contact forces unless the underlying bone shape is also addressed. Correcting the cartilage damage and correcting the impingement morphology are therefore two separate clinical tasks, and surgeons typically consider both together.

What ChondroFiller is — and what it is not

Think of ChondroFiller as a temporary scaffolding frame placed inside the pothole in the joint surface. The frame itself does not fill the hole permanently — instead, the body's own progenitor cells migrate in, do the repair work, and the collagen framework gradually integrates with the surrounding tissue. That biological sequence is what the manufacturer means by acellular matrix-induced chondrogenesis, and it is meaningfully different from what other injectable products do.

ChondroFiller is a CE-marked Class III medical device — a purified, murine-derived Type I/III collagen supplied as a liquid gel. Injected into a focal cartilage defect, it sets irreversibly within 3–5 minutes at body temperature, forming a stable, structured matrix that bonds to the surrounding native cartilage borders. The rapid gelling is a design feature rather than a side-effect: it allows the scaffold to stay anchored inside the defect rather than dispersing into the joint cavity.

Two comparisons are worth making explicit. Hyaluronic acid (viscosupplementation) lubricates the joint fluid — it does not form a structural matrix and does not recruit repair cells. Polyacrylamide hydrogel (Arthrosamid / PAAG) occupies space within the joint as a long-term cushion — it is a filler, not a regenerative scaffold, and it does not biodegrade. ChondroFiller works through a different mechanism entirely: it acts as a chemotactic signal, drawing the patient's own stem cells and chondrocyte precursors from the adjacent synovium and subchondral bone into the defect site, where they are thought to mature and deposit new cartilage matrix as the collagen framework biodegrades over time.

It is important not to overstate this. ChondroFiller supports the body's own repair processes within a focal defect; it does not guarantee cartilage regrowth, and the quality and durability of the repair tissue depend on factors including defect size, the patient's biology, and — as the previous section explained — whether the impingement mechanics driving the original damage have been addressed.

The 3–5 minute setting window has a direct clinical implication: the gel must reach the defect precisely, not the surrounding joint space. That single requirement is why ultrasound guidance is not optional for this treatment.

Why ultrasound guidance is non-negotiable for hip delivery

Delivery method matters here more than it does for most joint injections, and the anatomy of the hip explains why.

The hip is one of the deepest joints in the body — a ball-and-socket set within a thick envelope of muscle. Published orthobiologics research suggests that up to 30% of intra-articular hip injections performed without imaging guidance fail to land at the target site at all. For a fluid such as hyaluronic acid, an imprecise landing is suboptimal but recoverable — the fluid disperses through the joint space. For ChondroFiller, it is a clinical failure. Because the gel sets irreversibly within minutes of contact with body temperature, material deposited in the surrounding joint cavity stays there; it cannot migrate into the defect pocket, and the chemotactic scaffold mechanism cannot proceed.

Ultrasound guidance changes this. Real-time imaging allows the clinician to confirm the needle tip is positioned within the defect itself — not adjacent to it — before the gel is released. Studies comparing techniques report approximately 100% accurate intra-articular placement with ultrasound versus approximately 72% with landmark-guided approaches. That 28-point gap translates directly into whether the treatment has any realistic chance of working.

A practical question worth asking before booking: does the provider use continuous ultrasound guidance throughout the procedure, or is the needle placed by surface landmark alone? For ChondroFiller specifically, the answer should be the former.

Which patients are suitable for the injection pathway

Suitability for ChondroFiller hip injection rests on four factors that a specialist assessment weighs together — none of them alone producing a clean yes or no.

The first is the defect itself, confirmed by MRI: ChondroFiller is designed for focal, full-thickness Grade III or IV cartilage damage, typically an isolated area of approximately 2–6 cm² with healthy surrounding borders. Diffuse wear across the joint surface is a different problem — the scaffold is designed to fill a pothole, not resurface an entire road.

The second is the mechanical environment: whether the cam or pincer morphology that originally drove the damage has been addressed. Repair tissue placed under the same ongoing mechanical stress is less likely to produce a durable result; this is usually managed alongside the injection or in a prior procedure.

Third is biological repair capacity — the patient's ability to recruit and mature the progenitor cells the scaffold is designed to attract. The published 26-patient cohort (Perez-Carro et al., 2021) required Tönnis Grade 0–1 joint status for surgical application. The injection pathway may accommodate some patients with moderate wear, where the scaffold may still provide a degree of cushioning effect even if a full regenerative response is less certain. There is no published age ceiling; biological reserve matters more than calendar age.

Fourth is timing: whether the joint retains enough structural integrity for repair to be meaningful, or whether a different pathway would better serve the patient.

A rough guide: a 45-year-old with a confirmed 3 cm² Grade IV acetabular lesion and corrected impingement morphology is likely a strong candidate. Someone presenting with bone-on-bone wear across the joint surface is not — a focal scaffold cannot substitute for a joint that needs replacing. Lincolnshire Hip's suitability assessment, led by Professor Paul Lee across clinics in Grantham and Sleaford, covers all four of these lenses before a pathway is recommended.

The outpatient procedure and what outcomes to expect

The appointment takes place in a clinic room, not an operating theatre. No general anaesthetic is required, and there is no surgical incision involved.

Once positioned on the couch, the clinician places an ultrasound probe over the hip and maps the joint in real time. A fine needle is guided continuously under imaging — confirmed within the defect itself before gel is released, not placed by surface landmark. The collagen gel is delivered into that space and sets in place within three to five minutes. Most patients leave the same day.

What the published data show

The strongest peer-reviewed reference for injectable ChondroFiller in the hip is the Perez-Carro et al. cohort (Journal of Hip Preservation Surgery, 2021; PMC8322278): 26 patients with full-thickness acetabular defects, reporting a mean improvement of approximately 33 points on the modified Harris Hip Score — a gain the authors considered clinically meaningful. The cohort is small, and the authors note that long-term outcome data are still maturing.

Broader figures — drawn from multiple published observational case series and clinical registry experience across centres — suggest that somewhere between 70 and 85% of suitable patients report meaningful symptom relief at three to five years. These are aggregate, observational estimates rather than the output of a randomised controlled trial; they should be read as indicative rather than individually predictive. No large-scale RCT specific to ChondroFiller in the hip has yet been published; the 2021 cohort remains the most methodologically rigorous reference point available.

Recovery compared with surgery

For patients weighing the injection pathway against arthroscopic repair, the practical difference is real. Post-surgical hip arthroscopy typically involves crutches for several weeks and a structured rehabilitation programme lasting several months. Following a ChondroFiller injection, most patients manage a cautious return to normal activity within days, with graded loading over the following weeks — no wound care, no theatre recovery, and no general anaesthetic to recover from.

Cost, access, and arranging an assessment in Lincolnshire

Funding is the first practical question most patients ask: ChondroFiller is not available on the NHS and is not routinely covered by major UK private health insurers, including Bupa and AXA. It is accessed on a self-funded basis. Indicative costs in the UK for the ultrasound-guided injection pathway fall in the range of approximately £6,500 to £9,500; patients should confirm current pricing directly with the treating clinic, as figures vary by provider and what the appointment package includes.

Not all hip clinics offer the injectable route. The research literature — including the Perez-Carro et al. 2021 cohort — describes arthroscopic surgical application; the outpatient injection pathway is a more recent development and is not yet widespread across the UK. Local access is therefore a meaningful consideration when choosing a provider.

Lincolnshire Hip, with clinics in Grantham and Sleaford, offers ChondroFiller as an ultrasound-guided outpatient injection. The service is led by Professor Paul Lee, and assessment covers the suitability framework outlined in the preceding section — defect characteristics, mechanical environment, biological reserve, and timing. An MRI review is the necessary starting point; no GP referral is required.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

For patients who have lived with FAI-related hip pain and a confirmed focal cartilage defect, the injection pathway represents a genuinely different option from surgery — not a compromise, but a distinct clinical route with its own evidence base. Whether it is the right next step depends on what the imaging shows; that is the conversation a specialist assessment is designed to begin.